Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.